Home LiteratureArticle Details
PMID: 31138299 Published · epublish English Journal Article Research Support, Non-U.S. Gov't

Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma.

Journal for immunotherapy of cancer ·Vol. 7 ·No. 1 ·2019-00-28 ·Pages 139

Ghatalia P, Gordetsky J, Kuo F, Dulaimi E, Cai KQ, Devarajan K, Bae S, Naik G, Chan TA, Uzzo R, Hakimi AA, Sonpavde G, Plimack E

Abstract

The tumor immune microenvironment has become the focus of research in clear cell renal cell carcinoma (ccRCC) due to its important role in immune surveillance post nephrectomy. This study investigates the correlation of tumor infiltrating immune cell characteristics with rates of recurrence following surgery in localized ccRCC. We morphologically identified and scored tumor infiltrating lymphocytes (TILs) in hematoxylin and eosin (H&E) stained slides of patients with localized ccRCC (stage ≥T1b excluding stage IV). The University of Alabama at Birmingham (UAB) dataset (n = 159) was used to discover and the Fox Chase Cancer Center (FCCC) dataset (n = 198) was used to validate the results of morphologic immune cell analysis. We then performed gene expression analysis using the Immune Profile panel by NanoString in the UAB cohort and identified immune cells and pathways associated with recurrence, followed by validation in the Cancer Genome Atlas (TCGA) ccRCC dataset. Infiltrating immune cell types were identified by gene expression deconvolution. The presence of TILs identified by morphology correlated with higher T cell, Th1, CD8+ T and Treg gene signatures. Recurrence was associated with lower T cells and higher neutrophils. Higher Teffector (Teff)/Treg ratio correlated with lower rate of recurrence and was validated in the TCGA dataset. Genes associated with adaptive immune response were downregulated in tumors that recurred. Unsupervised hierarchical clustering identified a subset of patients with over-expression of adaptive response genes including CD8, CD3, GZMA/B, PRF1, IDO1, CTLA4, PDL1, ICOS and TIGIT. These patients had higher morphologic lymphocyte infiltration and T cell gene expression. Higher levels of TILs identified by morphology correlated with higher rates of recurrence in our discovery dataset but not in our validation set. Recurrence of ccRCC following surgery was associated with lower T cell infiltrate, lower adaptive immune response and higher neutrophil gene expression. Presence of higher Teff/Treg ratio correlated with lower recurrence.

Keywords
Immune cell Immunotherapy Localized Renal cell carcinoma Tumor infiltrating lymphocytes
MeSH Terms
Carcinoma, Renal Cell/immunology Female Gene Expression/genetics Humans Immunotherapy/methods Kidney Neoplasms/immunology Lymphocytes, Tumor-Infiltrating/immunology Male Middle Aged Prognosis Tumor Microenvironment
Authors & Affiliations
13 authors, click to expand affiliations / ORCID
Ghatalia Pooja
Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA, 19111, USA. Pooja.ghatalia@tuhs.temple.edu.
Gordetsky Jennifer
University of Alabama at Birmingham, 1802 6th Ave S, Birmingham, AL, 35233, USA.
Kuo Fengshen
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
Dulaimi Essel
Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA, 19111, USA.
Cai Kathy Q
Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA, 19111, USA.
Devarajan Karthik
Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA, 19111, USA.
Bae Sejong
University of Alabama at Birmingham, 1802 6th Ave S, Birmingham, AL, 35233, USA.
Naik Gurudatta
University of Alabama at Birmingham, 1802 6th Ave S, Birmingham, AL, 35233, USA.
Chan Timothy A
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
Uzzo Robert
Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA, 19111, USA.
Hakimi A Ari
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
Sonpavde Guru
University of Alabama at Birmingham, 1802 6th Ave S, Birmingham, AL, 35233, USA. | Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA.
Plimack Elizabeth
Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA, 19111, USA.
References (25)
25 references, click to expand
  1. The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer.
    Br J Cancer. 2003 Nov 17;89(10):1906-8 PMID: 14612901
  2. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.
    J Clin Oncol. 2010 Jan 1;28(1):105-13 PMID: 19917869
  3. Tumour-infiltrating macrophages and clinical outcome in breast cancer.
    J Clin Pathol. 2012 Feb;65(2):159-63 PMID: 22049225
  4. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin.
    Clin Cancer Res. 2013 Aug 1;19(15):4079-91 PMID: 23785047
  5. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.
    Immunity. 2013 Oct 17;39(4):782-95 PMID: 24138885
  6. CD40 expression in renal cell carcinoma is associated with tumor apoptosis, CD8(+) T cell frequency and patient survival.
    Hum Immunol. 2014 Jul;75(7):614-20 PMID: 24801648
  7. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.
    Ann Oncol. 2015 Feb;26(2):259-71 PMID: 25214542
  8. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial.
    Clin Cancer Res. 2015 Mar 1;21(5):1071-7 PMID: 25538263
  9. Molecular and genetic properties of tumors associated with local immune cytolytic activity.
    Cell. 2015 Jan 15;160(1-2):48-61 PMID: 25594174
  10. limma powers differential expression analyses for RNA-sequencing and microarray studies.
    Nucleic Acids Res. 2015 Apr 20;43(7):e47 PMID: 25605792
  11. Hiding in the dark: uncovering cancer drivers through image-guided genomics.
    Genome Biol. 2014 Dec 20;15(12):563 PMID: 25608759
  12. Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer.
    Clin Cancer Res. 2015 Jul 1;21(13):3031-40 PMID: 25688160
  13. Robust enumeration of cell subsets from tissue expression profiles.
    Nat Methods. 2015 May;12(5):453-7 PMID: 25822800
  14. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy.
    Genome Biol. 2016 Aug 22;17(1):174 PMID: 27549193
  15. Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma.
    Clin Cancer Res. 2017 Aug 1;23(15):4416-4428 PMID: 28213366
  16. Adjuvant Sunitinib in Renal-Cell Carcinoma.
    N Engl J Med. 2017 Mar 2;376(9):893 PMID: 28249133
  17. Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial.
    JAMA Oncol. 2017 Sep 1;3(9):1249-1252 PMID: 28278333
  18. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.
    J Clin Oncol. 2017 Dec 10;35(35):3916-3923 PMID: 28902533
  19. Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study.
    Clin Cancer Res. 2018 Apr 1;24(7):1554-1561 PMID: 29374054
  20. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
    N Engl J Med. 2018 Apr 05;378(14):1277-1290 PMID: 29562145
  21. Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy.
    J Natl Cancer Inst. 2019 Jan 1;111(1):69-77 PMID: 29788230
  22. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.
    Nat Med. 2018 Jun;24(6):749-757 PMID: 29867230
  23. Spatial Architecture and Arrangement of Tumor-Infiltrating Lymphocytes for Predicting Likelihood of Recurrence in Early-Stage Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2019 Mar 1;25(5):1526-1534 PMID: 30201760
  24. Quantitative Analyses of the Tumor Microenvironment Composition and Orientation in the Era of Precision Medicine.
    Front Oncol. 2018 Sep 25;8:390 PMID: 30319963
  25. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial.
    Ann Oncol. 2018 Dec 1;29(12):2371-2378 PMID: 30346481
Article Info
Journal
Journal for immunotherapy of cancer
Abbr.
J Immunother Cancer
ISSN
2051-1426
Published
2019-00-28
Epub
2019-00-28
Pages
139
Language
English
Region
England
NLM ID
101620585
PMCID
PMC6540413
Subset
IM
Grants
NCI NIH HHS · P30 CA008748 · United States
NCI NIH HHS · P30 CA013148 · United States
NCI NIH HHS · R35 CA232097 · United States
Corrections
ErratumIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com